产品
编 号：F653164
分子式：C25H48N2O5Si
分子量：484.74
分子式：C25H48N2O5Si
分子量：484.74
产品类型
规格
价格
是否有货
结构图
CAS No: 1000313-40-5
产品详情
生物活性：
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey. UK-101 induces cell apoptosis and can be used for the study of prostate cancer.
体内研究：
UK-101 (intraperitoneal injection; 1-3 mg/kg; twice a week; 3 weeks) decreases tumor volume as a dose-dependent manner, it significantly decreases tumor volume at a dose of 3 mg/kg. Additionally, UK-101-treated mice is suffering less systemic toxicity and the weights of mice treated with UK-101 remains steady over the 3-week treatment period.Animal Model:Subcutaneously implanted PC-3 cells in 6-week-old male BALB/c athymic nude mice
Dosage:1 mg/kg; 3 mg/kg
Administration:Intraperitoneal injection; twice a week; 3 weeks
Result:Inhibited tumour growth in the prostate cancer mouse xenograft model.
体外研究：
UK-101 (2-8 μM; 24 hours) induces cell cycle arrest and increases the number of the PC-3 cells arrest in G1 phase of the cell cycle.UK-101 (2-8 μM; 24 hours) induces cell apoptosis, shows a minimal increase in late apoptosis, but has no significant increase in early apoptosis.UK-101 (1-8 μM; 24 hours) induces cells accumulation in the G1 phase of the cell cycle, it increases p27 accumulation and significantly increases?PARP cleavage as a dose-dependent manner.
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey. UK-101 induces cell apoptosis and can be used for the study of prostate cancer.
体内研究：
UK-101 (intraperitoneal injection; 1-3 mg/kg; twice a week; 3 weeks) decreases tumor volume as a dose-dependent manner, it significantly decreases tumor volume at a dose of 3 mg/kg. Additionally, UK-101-treated mice is suffering less systemic toxicity and the weights of mice treated with UK-101 remains steady over the 3-week treatment period.Animal Model:Subcutaneously implanted PC-3 cells in 6-week-old male BALB/c athymic nude mice
Dosage:1 mg/kg; 3 mg/kg
Administration:Intraperitoneal injection; twice a week; 3 weeks
Result:Inhibited tumour growth in the prostate cancer mouse xenograft model.
体外研究：
UK-101 (2-8 μM; 24 hours) induces cell cycle arrest and increases the number of the PC-3 cells arrest in G1 phase of the cell cycle.UK-101 (2-8 μM; 24 hours) induces cell apoptosis, shows a minimal increase in late apoptosis, but has no significant increase in early apoptosis.UK-101 (1-8 μM; 24 hours) induces cells accumulation in the G1 phase of the cell cycle, it increases p27 accumulation and significantly increases?PARP cleavage as a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备